Inhibition of SGK1 in the treatment of heart conditions

1. A method for treatment of a cardiovascular disease in a subject, the method comprising, administering to the subject a therapeutically effective amount of at least one SGK1 inhibitor having the Formula 1:

wherein:

n is 1, 2, 3, 4, or 5;

each R is independently selected from the group consisting of hydrogen, a halogen, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkyl, C 1 -C 6 haloalkoxy, CN, CO 2 H, CO 2 (C 1 -C 6 alkyl), CO 2 (C 1 -C 6 haloalkyl), —OH, —NH 2 , —NH(C 1 -C 6 alkyl), —N(C 1 -C 6 alkyl) 2 , —SH, and —S(C 1 -C 6 alkyl);

or a pharmaceutically acceptable salt thereof,

wherein the cardiovascular disease is selected from the group consisting of heart failure, arrhythmia, ischemic injury, ischemic infarction, cardiac fibrosis, vascular proliferation, restenosis, dilated cardiomyopathy, and stent failure.

2. The method of claim 1 , wherein the cardiovascular disease is any one of the group selected from heart failure, arrhythmia, ischemic injury, ischemic infarction, cardiac fibrosis, vascular proliferation, restenosis, or stent failure.

3. The method of claim 1 , wherein the cardiovascular disease is dilated cardiomyopathy.

4. The method of claim 3 , wherein the dilated cardiomyopathy is genetic.

5. The method of claim 3 , wherein the dilated cardiomyopathy is acquired.

6. The method of claim 4 , wherein the dilated cardiomyopathy is characterized by a mutation in the MYH6 gene.

7. The method of claim 4 , wherein the dilated cardiomyopathy is characterized by a mutation in the MYH7 gene.

8. The method of claim 4 , wherein the dilated cardiomyopathy is characterized by a mutation in the SCN5A gene.

9. The method of claim 1 , wherein the SGK1 inhibitor is selected from:

or a pharmaceutically acceptable salt thereof.